Nancy Phelan, Wyeth
S
Nancy Phelan
ED, Consumer Communications and E-marketing, Wyeth
MOST RECENT HIT: Launched birth control pill Lybrel
ADDED VALUE: "Best Practices" brainiac
I saw firsthand the impact that disease can have on the person who has the disease, but also on the family," says Nancy Phelan. Her sister was often hospitalized with seer asthma, and not until Theo-Dur hit the market could she live a "normal" life. When it came to a career choice, Phelan chose pharma—Schering-Plough, the maker of Theo-Dur. After her field service, she rose fast into management, helping to take the allergy med Claritin over the counter. Winging it to Wyeth, she now helps with marketing strategy and best practices for all pharmaceutical brands. Phelan has a reputation for taking ethics as seriously as sales—a distinction for which she credits her industry mentors. "If you compromise once, you're going to compromise again," she says. As for her generation of new leaders, she says, "There does seem to be a new openness to new solutions, and an optimism that we can actually lead the change in healthcare, rather than only reacting once that happens."
Nancy Phelan
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
